Vanguard Global Advisers
VNRX icon

Vanguard Global Advisers’s VolitionRx Ltd VNRX Stock Holding History

Vanguard Global Advisers’s Portfolio VNRX Stock Details VNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-686
Closed -$2.77K – 3740
2026
Q1 		$2.77K Buy
+686
New +$3.28K ﹤0.01% 3600

Other funds holding VNRX

LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return

Vanguard Global Advisers's VNRX Position: Q2 2026 in Review

Vanguard Global Advisers sold out of VolitionRx Ltd (VNRX) in Q2 2026, closing a stake of 686 shares — an estimated $2.77K sold.

Vanguard Global Advisers first reported a position in VNRX in Q1 2026 and held it in 1 quarter. The position peaked at $2.77K in Q1 2026. 25 funds tracked by Wall St. Rank hold VNRX as of Q2 2026.

  • Vanguard Global Advisers reported no remaining VolitionRx Ltd position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 686 VolitionRx Ltd shares in Q2 2026, an estimated $2.77K.
  • Vanguard Global Advisers first reported a position in VolitionRx Ltd in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's VolitionRx Ltd position peaked at $2.77K in Q1 2026.
  • 25 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.